Treatment with lenabasum can effectively prevent inflammation and induce pro-resolving signals in airway immune cells from patients with cystic…
Articles by Alice Melão, MSc
Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco (ivacaftor) and tezacaftor (VX-661) can improve…
Treatment with a combo of Proteostasis Therapeutics’ investigational CFTR modulator therapies — PTI-808, a potentiator, plus PTI-801, a…
AzurRx BioPharma is planning a multi-center Phase 2 trial to be conducted in the United States and Europe to…
Mutations in the CFTR gene that associate with severe disease can also lead to cardiac problems — specifically, the development of…
Beginning Oct. 1, the cystic fibrosis (CF) targeted therapy Orkambi (lumacaftor/ivacaftor) will be included on Australia’s Pharmaceutical Benefits Scheme.
Using a computer modeling method, a research team at the University of Copenhagen, Denmark, demonstrated some of the early…
Patients with cystic fibrosis (CF) have a greater risk of developing abnormalities in their retinal veins, which can impair…
Topline data from a Phase 2b trial showed that the investigative therapy acebilustat taken once daily can reduce the number and…
Vertex Pharmaceuticals’ Symkevi (tezacaftor/ivacaftor) is one step closer to being approved in the European Union as a treatment…